# IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Source: https://onco.cc/trials/nct06119685/  
OnCo record `nct06119685` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rituximab, Daratumumab, Aldesleukin in multiple myeloma and hodgkin lymphoma, run by Indapta Therapeutics, INC., now recruiting.

## Summary

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers is a phase 1/2 interventional study registered as NCT06119685 by Indapta Therapeutics, INC., with 128 participants planned, started 2023-10-25 and due to reach its primary completion in 2025-12-30. Interventions recorded: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide. Conditions listed: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06119685
- Phase: 1/2
- Setting: Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Sponsor: Indapta Therapeutics, INC.
- Enrolled: 128

## Sources

- ClinicalTrials.gov NCT06119685: https://clinicaltrials.gov/study/NCT06119685

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Mesna](https://onco.cc/drugs/mesna/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Indapta Therapeutics](https://onco.cc/companies/indapta-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06119685.json